WITHDRAWN: Treatment discontinuation with selective serotonin reuptake inhibitors (SSRIs) versus tricyclic antidepressants (TCAs) - PubMed (original) (raw)

Review

WITHDRAWN: Treatment discontinuation with selective serotonin reuptake inhibitors (SSRIs) versus tricyclic antidepressants (TCAs)

C Barbui et al. Cochrane Database Syst Rev. 2007.

Abstract

Background: Selective serotonin reuptake inhibitors are thought to have better discontinuation rates (i.e. less people dropping out) than tricyclic and heterocyclic antidepressant drugs. It is important to quantify the drop-out rates of different antidepressant drugs in order to have a better understanding of the relative tolerability of these drugs.

Objectives: To assess the comparative tolerability of selective serotonin reuptake inhibitors and tricyclic/heterocyclic antidepressant drugs.

Search strategy: We searched the Cochrane Collaboration Depression, Anxiety and Neurosis Controlled Trials Registers (1997 to 1999), MEDLINE (1966 to 1999), EMBASE (1974 to 1999) We also searched specialist journals, the reference lists of relevant papers and previous systematic reviews, conference abstracts and government documents. Representatives of the pharmaceutical industry were contacted.

Selection criteria: Parallel group randomised controlled trials comparing selective serotonin reuptake inhibitors with tricyclic or heterocyclic antidepressants in people with depression.

Data collection and analysis: Two reviewers independently extracted data and a third reviewer checked any cases of disagreement.

Main results: We included 136 trials. The selective serotonin reuptake inhibitors showed less participants dropping out compared to the tricyclic/heterocyclic group (odds ratio 1.21, 95% confidence interval 1.12 to 1.30). A statistically significant difference was found in total drop-outs between the selective serotonin reuptake inhibitors and the old tricyclics as well as the newer tricyclics. When the selective serotonin reuptake inhibitors were compared to the heterocyclic antidepressants, there was a non significant difference favouring the selective serotonin reuptake inhibitors. The poor tolerability profile of the old tricyclics was explained by differences in drop-outs for side-effects, but not for inefficacy.

Authors' conclusions: Whilst selective serotonin reuptake inhibitors do appear to show an advantage over tricyclic drugs in terms of total drop-outs, this advantage is relatively modest. This has implications for pharmaco-economic models, some of which may have overestimated the difference of drop-out rates between selective serotonin reuptake inhibitors and tricyclic antidepressants. These results are based on short-term randomised controlled trials, and may not generalise into clinical practice.

PubMed Disclaimer

Update of

Selective serotonin reuptake inhibitors versus tricyclic and heterocyclic antidepressants: comparison of drug adherence.
Barbui C, Hotopf M, Freemantle N, Boynton J, Churchill R, Eccles MP, Geddes JR, Hardy R, Lewis G, Mason JM. Barbui C, et al. Cochrane Database Syst Rev. 2000;(4):CD002791. doi: 10.1002/14651858.CD002791. Cochrane Database Syst Rev. 2000. PMID: 11034764 Updated. Review.

Cited by

Repeated Yueju, But Not Fluoxetine, Induced Sustained Antidepressant Activity in a Mouse Model of Chronic Learned Helplessness: Involvement of CaMKII Signaling in the Hippocampus.
Zou Z, Huang J, Yang Q, Zhang Y, Xu B, Wang P, Chen G. Zou Z, et al. Evid Based Complement Alternat Med. 2022 Feb 24;2022:1442578. doi: 10.1155/2022/1442578. eCollection 2022. Evid Based Complement Alternat Med. 2022. PMID: 35251201 Free PMC article.
[Tricyclic antidepressants for initial treatment of depressive episodes? Con].
Adli M, Berger M. Adli M, et al. Nervenarzt. 2016 May;87(5):561-2. doi: 10.1007/s00115-015-0032-6. Nervenarzt. 2016. PMID: 26628046 German. No abstract available.
Double-Blind Randomized Clinical Trial of the Efficacy of Venlafaxine Versus Citalopram in the Treatment of the Acute Phase of Major Depressive Disorder.
Hosseini F, Amini F, Yassini Ardekani SM, Shariat N, Nadi M. Hosseini F, et al. Iran J Psychiatry Behav Sci. 2015 Jun;9(2):e1041. doi: 10.17795/ijpbs1041. Epub 2015 Jun 1. Iran J Psychiatry Behav Sci. 2015. PMID: 26286846 Free PMC article.
Ketamine as antidepressant? Current state and future perspectives.
Hasselmann HW. Hasselmann HW. Curr Neuropharmacol. 2014 Jan;12(1):57-70. doi: 10.2174/1570159X113119990043. Curr Neuropharmacol. 2014. PMID: 24533016 Free PMC article.
Mirtazapine versus other antidepressive agents for depression.
Watanabe N, Omori IM, Nakagawa A, Cipriani A, Barbui C, Churchill R, Furukawa TA. Watanabe N, et al. Cochrane Database Syst Rev. 2011 Dec 7;(12):CD006528. doi: 10.1002/14651858.CD006528.pub2. Cochrane Database Syst Rev. 2011. PMID: 22161405 Free PMC article. Review.

WITHDRAWN: Treatment discontinuation with selective serotonin reuptake inhibitors (SSRIs) versus tricyclic antidepressants (TCAs) - PubMed (original) (raw)